Matches 1 - 50 out of 127 1 2 3 >


Match Document Document Title
US20120100229 Treatment and Prevention of White Matter Injury with KATP Channel Activators  
The present invention includes a method of treating or preventing a CNS white matter injury in a patient in need thereof. The invention also includes a method of stimulating proliferation of a CNS...
US20130039905 Diazoxide For Use In The Treatment Or Prevention Of A Central Nervous System (CNS) Autoimmune Demyelinating Disease  
The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple...
US20120027723 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION  
The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the...
US20120164218 SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME  
Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.
US20130210778 FORMULATION FOR THE PREVENTION OF CARDIOVASCULAR DISEASE  
This invention relates to a method for the prevention of cardiovascular disease, a formulation for the prevention of cardiovascular disease, the use of specified active principals for the...
US20120053172 USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS  
The present invention relates to a method for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, said method comprising administering to...
US20110236473 STABLE ALISKIREN FORMULATIONS  
An oral pharmaceutical formulation, made up of croscarmellose sodium and internal granules including a pharmaceutically acceptable salt or polymorph of aliskiren and stearic acid.
US20110312947 Method of improving ß-adrenergic receptor function  
The present invention relates to a method of increasing the sensitivity of a hyperinsulinemic patient to the anti-obesity and antidiabetic effects of a β adrenergic receptor (βAR) agonist. The...
US20110189281 TELMISARTAN AND HYDROCHLOROTHIAZIDE COMBINATION THERAPY  
A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of...
US20130116215 COMBINATION THERAPIES FOR TREATING NEUROLOGICAL DISORDERS  
The invention features novel pharmaceutical combinations useful for the treatment of neurological diseases, specifically neurodegenerative diseases. The novel pharmaceutical combinations of the...
US20140066396 METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS  
The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-az a-tricyclo[6.2.1.02,7]undec-5-en-5-yl...
US20110229438 METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS  
The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-az a-tricyclo[6.2.1.02,7]undec-5-en-5-yl...
US20120302555 METHOD OF TREATMENT USING EPROSARTAN  
The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension,...
US20100029576 Diazoxide for the treatment of Friedreich's Ataxia  
A pharmaceutical preparation treats Friedreich's ataxia and treats or prevents pathologies related thereto. In particular, the pharaceutical preparation concerns the use of diazoxide or...
US20140178471 MULTI-LAYERED RELEASE FORMULATION  
The present invention in general relates to a pharmaceutical dosage form comprising a multi-layered release formulation formed by co-extrusion. Said formulation in particular comprises a core...
US20140073574 THERAPY FOR COMPLICATIONS OF DIABETES  
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective...
US20130178424 THERAPY FOR COMPLICATIONS OF DIABETES  
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective...
US20110306601 PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION  
Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor...
US20130109680 METHODS AND COMPOSITIONS FOR AMELIORATING THIAZIDE INDUCED HYPERLIPIDEMIA  
Male Disclosed herein are compositions for ameliorating the lipid producing effects of thiazide therapy. Particularly exemplified herein are compositions containing a thiazide and allopurinol, or...
US20110165235 DIRECTLY PRESSED ALISKIREN TABLETS  
The invention relates to pharmaceutical compositions which contain the active agent Aliskiren and are suitable for the production of tablets by dry pressing, so that prior wet granulation can be...
US20130216625 TREATMENT OF INSULIN RESISTANCE OR DISEASES ASSOCIATED WITH INSULIN RESISTANCE  
The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a...
US20100324019 Use of Riboflavin in the Treatment of Hypertension  
The invention provides the use of riboflavin in the manufacture of a medicament for the treatment or prophylaxis of elevated blood pressure in a subject homozygous or heterozygous for the MTHFR...
US20120114753 MULTI-LAYER TABLET COMPRISING EFFERVESCENT LAYER  
The present invention provides a multi-layer tablet comprising: an effervescent layer comprising hydrochlorothiazide or amlodipine or its salt as an active ingredient, a carbonate salt, and an...
US20110223211 PHARMACEUTICAL FORMULATIONS CONTAINING IRBESARTAN  
The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally...
US20100003321 SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME  
Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.
US20060159747 Telmisartan and hydrochlorothiazide combination therapy  
A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of...
US20140134247 PHARMACEUTICAL COMPOSITION  
A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.
US20140364425 SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF  
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic,...
US20130309301 SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF  
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic,...
US20130040942 SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF  
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic,...
US20120238554 SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF  
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic,...
US20150190399 NEW DIFFERENTIAL-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE PRINCIPLES  
This invention relates to a differential release formulation containing an angiotensin-II receptor antagonist, a calcium channel blocker and a diuretic, wherein the said pharmaceutical composition...
US20120064158 DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL  
A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine besylate...
US20110229571 Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker  
Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and...
US20090036432 Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic  
The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising (i) an AT1-receptor antagonist or a pharmaceutically acceptable salt...
US20080227774 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS  
The invention is directed to 5,5-disubstituted-indolizinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
US20080214529 SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS  
The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
US20150147394 PHARMACEUTICAL COMPOSITION CONTAINING FIMASARTNA AND HYDROCHLOROTHIAZIDE  
The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation,...
US20090156585 ORGANIC COMPOUNDS  
A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension.
US20110038898 DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL  
A pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine as active...
US20090023714 COMBINED PREPARATION OF A THIAZIDE DIURETIC AND A LOOP DIURETIC  
The invention relates to pharmaceutical preparations which contain a combination of a thiazide diuretic and a low-dose loop diuretic and which are particularly useful for treating hypertension and...
US20110110890 Novel Inhibitors of Hepatitis C Virus Replication  
The embodiments provide compounds of the general Formula I and compound 105S, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further...
US20110081426 AMINOTHIAZOLE MODULATORS OF BETA-3-ADRENORECEPTOR  
The present invention relates to new aminothiazole modulators of beta-3-adrenoreceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
US20090203679 GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS  
The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective...
US20110190277 PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES  
A method for the prevention or treatment of a cardiovascular, cardiopulmonary, or renal disease or condition in a human or mammal patient, the method comprising administering to the patient in...
US20100247649 PHARMACEUTICAL FORMULATIONS COMPRISING TELMISARTAN AND HYDROCHLOROTHIAZIDE  
Pharmaceutical tablets comprising a first layer formulated for immediate release of telmisartan from a dissolving matrix and a second layer formulated for immediate release of hydrochlorothiazide...
US20110301082 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE  
Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type (2) diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also...
US20110281795 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE  
Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also...
US20070196510 Method for treating resistant hypertension  
A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a...
US20100278909 PROCESS FOR FORMING SOLID ORAL DOSAGE FORMS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS  
A method for producing granules of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, which comprises: a) mixing the angiotensin II receptor antagonist or...

Matches 1 - 50 out of 127 1 2 3 >